Cambridge Healthtech Institute’s Ninth Annual
Part One: Adjuvants, TLRs & DNA Vaccines
August 11-12, 2014
Vaccines are widely recognized as the single most important way to protect human health, yet problems of efficacy persist, baffling researchers. Adjuvanting vaccines has emerged as a promising approach to create more efficacious vaccines and reduce costs, yet safety issues continue to arise, and challenges for developing new adjuvants persist.
The Ninth annual “Novel Vaccines” meeting explores the breakthroughs in Adjuvant science including TLRs and new antigen combinations. Adjuvant Safety and Mode of Action will be addressed along with a discussion focused on how to develop new adjuvants, and get them approved. Toll-Like Receptors will also be discussed, as will DNA and RNA-Based vaccines. New approaches for developing vaccines against disease applications will be explored, along with a focus on Pertussis that highlights the recent spike in cases.
Opening Keynote Presentation:
The Regulatory Outlook for Future Vaccine Adjuvants
Norman W. Baylor, Ph.D., President and CEO, Biologics Consulting Group, Inc.
Adjuvant Mechanism of Action
Eugene Maraskovsky, Ph.D., Senior Director, Head, Cell Biology and Physiolocy, CSL Limited
Adjuvanting Vaccines Using Laser Therapy
Mark C. Poznansky, M.D., Ph.D., Associate Professor, Medicine, Harvard Medical School; Director, Vaccine and Immunotherapy Center, Infectious Diseases Medicine, Massachusetts General Hospital
Systematic Analysis of Responses Induced by a TLR2 Ligand Immune Adjuvant
Lee M. Wetzler, M.D., Associate Program Director, Research, Infectious Diseases, Professor, Medicine, Associate Professor, Microbiology, Boston University School of Medicine
RNA: The New Revolution in Nucleic Acid Vaccines
Andrew Geall, Ph.D., RNA Vaccine Platform Leader, Vaccine Delivery & Formulation Research, Novartis Vaccines & Diagnostics, Inc.
Monitoring B Cell Development and Ig Gene Usage for Vaccine Development
Shan Lu, M.D., Ph.D., Professor, University of Massachusetts Medical School
Synthetic Influenza Vaccine Viruses
Philip R. Dormitzer, M.D., Ph.D., Head, US Research, Global Head, Virology, Vice President, Novartis Vaccines
Development of a Second Generation Recombinant Influenza Vaccine Having Room Temperature Stability
Kathy Holtz, Ph.D., Formulation Development Scientist, Protein Sciences Corporation
Development of an Adjuvanted Recombinant Envelope-Based Subunit Vaccine against Dengue
Danilo R. Casimiro, Ph.D., Executive Director, Vaccine Research, Merck & Co.
Pertussis Resurgence – 2014: Facts, Fiction, Myths and Misconceptions
James D. Cherry, M.D., MSc, Distinguished Research Professor, Pediatrics, David Geffen School of Medicine, UCLA; Attending Physician, Pediatric Infectious Diseases, Mattel Children’s Hospital
Quantification of the Adenylate Cyclase Toxin of Bordetella pertussis in vitro and during Respiratory Infection
Erik L. Hewlett, M.D., Professor, Medicine, Infectious Diseases and International Health, Professor, Medicine and Microbiology, Immunology and Cancer Biology, University of Virginia School of Medicine